Merck & Co., Inc. Stock price

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX 12:12:21 2024-03-28 pm EDT 5-day change 1st Jan Change
131.6 USD -0.08% Intraday chart for Merck & Co., Inc. +6.49% +20.75%
Sales 2024 * 63.76B Sales 2025 * 68.03B Capitalization 334B
Net income 2024 * 19.74B Net income 2025 * 22.12B EV / Sales 2024 * 5.54 x
Net Debt 2024 * 19.56B Net Debt 2025 * 7.5B EV / Sales 2025 * 5.02 x
P/E ratio 2024 *
16.8 x
P/E ratio 2025 *
14.6 x
Employees 71,000
Yield 2024 *
2.36%
Yield 2025 *
2.5%
Free-Float 70.71%
More Fundamentals * Assessed data
Dynamic Chart
1 week+6.50%
Current month+3.54%
1 month+2.70%
3 months+21.04%
6 months+26.22%
Current year+20.76%
More quotes
1 week
123.22
Extreme 123.22
133.10
1 month
119.23
Extreme 119.23
133.10
Current year
109.16
Extreme 109.16
133.10
1 year
99.14
Extreme 99.14
133.10
3 years
70.89
Extreme 70.89
133.10
5 years
65.25
Extreme 65.25
133.10
10 years
45.69
Extreme 45.69
133.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 67 15-08-31
Director/Board Member 69 18-02-28
More insiders
Date Price Change Volume
24-03-28 131.6 -0.08% 2 781 869
24-03-27 131.8 +4.96% 16,061,581
24-03-26 125.5 +0.17% 8,864,402
24-03-25 125.3 +1.18% 7,605,755
24-03-22 123.8 +0.19% 7,022,502

Delayed Quote Nyse, March 28, 2024 at 10:48 am EDT

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
131.8 USD
Average target price
136.2 USD
Spread / Average Target
+3.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse